Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival
Numerous observational and randomized, controlled studies have suggested a protective effect of regular use of aspirin on colorectal neoplasias.1-7 The favorable outcome that has been associated with aspirin use after colorectal cancer is diagnosed8-10 suggests that aspirin is a promising agent for adjuvant therapy. Accumulating data suggest that colorectal cancers are a heterogeneous group of diseases that potentially have differential responses to treatment.11 The effect of postdiagnosis aspirin use on survival appears to differ according to tumor expression of PTGS2 (HGNC:9605, the official symbol for prostaglandin-endoperoxide synthase 2, also known as cyclooxygenase-2) as assessed by immunohistochemical techniques.8 Considering . . .